Sibylle Loibl
- Cancer Research top 0.01%
- Breast Cancer Treatment Studies 269
- Cancer Genomics and Diagnostics 64
- Oncology top 0.02%
- HER2/EGFR in Cancer Research 195
- Cancer Treatment and Pharmacology 187
- Cancer Risks and Factors 47
- Pulmonary and Respiratory Medicine top 0.05%
- Advanced Breast Cancer Therapies 170
- Pathology and Forensic Medicine top 0.1%
- Breast Lesions and Carcinomas 59
- Genetics top 0.5%
-
- Monoclonal and Polyclonal Antibodies Research 39
- Co-authors
- Gϋnter von MinckwitzCarsten DenkertMichael UntchJens HuoberFabrice AndréLuca GianniSherene LoiJens‐Uwe Blohmer
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Sibylle Loibl
557 papers receiving 29.0k citations
Hit Papers
Peers
Comparison fields: 5 of 154
- Cancer Research 13.4k
- Oncology 19.6k
- Pulmonary and Respiratory Medicine 8.4k
- Pathology and Forensic Medicine 3.9k
- Genetics 1.7k
Countries citing papers authored by Sibylle Loibl
This map shows the geographic impact of Sibylle Loibl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sibylle Loibl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sibylle Loibl more than expected).
Fields of papers citing papers by Sibylle Loibl
This network shows the impact of papers produced by Sibylle Loibl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sibylle Loibl. The network helps show where Sibylle Loibl may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Sibylle Loibl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 23 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 2 | |
| 6 | 2023 | 3 | |
| 7 | 2023 | 0 | |
| 8 | 2022 | 9 | |
| 9 | 2021 | 17 | |
| 10 | Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guidelinebreakdown → | 2021 | 592 |
| 11 | 2020 | 26 | |
| 12 | Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancerbreakdown → | 2019 | 1565 |
| 13 | 2018 | 8 | |
| 14 | The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trialbreakdown → | 2018 | 401 |
| 15 | 2017 | 82 | |
| 16 | 2016 | 34 | |
| 17 | 2014 | 78 | |
| 18 | 2012 | 0 | |
| 19 | 2008 | 64 | |
| 20 | 2007 | 54 |
About Sibylle Loibl
Sibylle Loibl is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 588 papers that have together received 29.5k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (269 papers), HER2/EGFR in Cancer Research (195 papers), Cancer Treatment and Pharmacology (187 papers), Advanced Breast Cancer Therapies (170 papers), Cancer Genomics and Diagnostics (64 papers), Breast Lesions and Carcinomas (59 papers), Cancer Risks and Factors (47 papers) and Monoclonal and Polyclonal Antibodies Research (39 papers). The work is most often cited by research in Cancer Research (13.4k citations), Oncology (19.6k citations) and Pulmonary and Respiratory Medicine (8.4k citations). Sibylle Loibl has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Gϋnter von Minckwitz, Carsten Denkert, Michael Untch, Jens Huober, Fabrice André, Luca Gianni, Sherene Loi, Jens‐Uwe Blohmer, Manfred Kaufmann and Nicholas C. Turner. Their work appears in journals such as New England Journal of Medicine, The Lancet and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.